Fertility preservation options for young women with breast cancer

Current Opinion in Obstetrics and Gynecology

Volumn 23, Issue 3, 2011, Pages 174-182

  Hulvat, Melissa C ^a   Jeruss, Jacqueline S ^b  

^a KALISPELL REGIONAL MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

breast cancer; chemotherapy; fertility preservation; oncofertility; ovarian function

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTRADIOL; FLUOROURACIL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GOSERELIN; INHIBIN B; LETROZOLE; LUTEINIZING HORMONE; METHOTREXATE; MUELLERIAN INHIBITING FACTOR; TAMOXIFEN; TRASTUZUMAB;

ADOPTION; AMENORRHEA; APOPTOSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONTROLLED OVARIAN STIMULATION; CRYOPRESERVATION; EMBRYO CRYOPRESERVATION; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FIBROSIS; GROUPS BY AGE; HORMONAL REGULATION; HUMAN; INFERTILITY THERAPY; MEDICAL DECISION MAKING; MENSTRUAL IRREGULARITY; OOCYTE; OOCYTE CRYOPRESERVATION; OOCYTE DONATION; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARIAN TISSUE PRESERVATION; OVARY FOLLICLE CELL; OVARY FOLLICLE MATURATION; OVARY FUNCTION; OVULATION INDUCTION; PRACTICE GUIDELINE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION SICKNESS; REPRODUCTIVE TOXICITY; REVIEW; SPERM DONOR; TISSUE PRESERVATION; TISSUE TRANSPLANTATION; TREATMENT PLANNING; VITRIFICATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FERTILITY; HUMANS; INFERTILITY, FEMALE; MEDICAL ONCOLOGY; OVARY;

EID: 79955977855     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e328345525a     Document Type: Review

References (67)

1. Cancer Facts & Figures 2010, American Cancer Society. [December 12, 2010]; Available from: http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/ documents/document/acspc-026238.pdf.
2. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24:2917-2931. (Pubitemid 46655598)
3. PartridgeAH, Gelber S, Peppercorn J, et al.Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22:4174-4183. (Pubitemid 41185188)
4. Canada AL, Schover LR. The psychosocial impact of interrupted childbearing in long-termfemale cancer survivors. Psychooncology2010. [Epub ahead of print]
5. Meirow D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. ClinObstetGynecol 2010; 53:727-739.
6. Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007; 30:126-132. (Pubitemid 46573245)
7. Lutchman Singh K, Muttukrishna S, Stein RC, et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 2007; 96:1808-1816. (Pubitemid 46912025)
8. Visser JA, Themmen AP. Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol 2005; 234 (1-2):81-86.
9. Anders C, Marcom PK, Peterson B, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008; 26:286-295. (Pubitemid 351329008)
10. Jung M, Shin HJ, Rha SY, et al. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with longterm follow-up. Ann Surg Oncol 2010; 17:3259-3268.
11. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004; 10:251-266.
12. Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril 2008; 90:1635-1639.
13. Swain SM, Land SR, Ritter MW, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 2009; 113:315-320.
14. Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010; 116:791-798.
15. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 24:1045-1051. (Pubitemid 46638800)
16. Maltaris T, Weigel M, Mueller A, et al. Cancer and fertility preservation: fertility preservation in breast cancer patients. Breast Cancer Res 2008; 10:206.
17. Gradishar WJ, Hellmund R. A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy. Clin Breast Cancer 2002; 2:282-286. (Pubitemid 34196270)
18. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 2001; 7:394-403. (Pubitemid 32655325)
19. Barthelmes L, Gateley CA. Tamoxifen and pregnancy. Breast 2004; 13:446-451. (Pubitemid 39618815)
20. Halakivi-Clarke L, Cho E, Onojafe I, et al. Maternal exposure to tamoxifen during pregnancy increases carcinogen-induced mammary tumorigenesis among female rat offspring. Clin Cancer Res 2000; 6:305-308. (Pubitemid 30065006)
21. Ginsberg JP. Educational paper: the effect of cancer therapy on fertility, the assessment of fertility and fertility preservation options for pediatric patients. Eur J Pediatr 2010. [Epub ahead of print]
22. Critchley HO, Wallace WH. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr 2005; 34:64-68.
23. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001; 7:535-543. (Pubitemid 33069611)
24. Maltaris T, Seufert R, Fischl F, et al. The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J ObstetGynecol Reprod Biol 2007; 130:148-155. (Pubitemid 46097248)
25. Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005; 62:738-744. (Pubitemid 40779763)
26. Mazonakis M, Varveris H, Damilakis J, et al. Radiation dose to conceptus resulting from tangential breast irradiation. Int J Radiat Oncol Biol Phys 2003; 55:386-391. (Pubitemid 36069097)
27. Antypas C, Sandilos P, Kouvaris J, et al. Fetal dose evaluation during breast cancer radiotherapy. Int J Radiat Oncol Biol Phys 1998; 40:995-999. (Pubitemid 28150819)
28. Noyes N, Porcu E, Bazzocchi Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed 2009; 18:769-776.
29. Donnez J, Squifflet J, Jadoul P, et al. Pregnancy and live birth after autotransplantation of frozen-thawed ovarian tissue in a patient with metastatic disease undergoing chemotherapy and hematopoietic stem cell transplantation. Fertil Steril 2010.
30. Lee MC, Gray J, Han HS, Plosker S. Fertility and reproductive considerations in premenopausal patients with breast cancer. Cancer Control 2010; 17:162-172.
31. Buster JE, The First Live. SRM [online]. 2007. http://www.obgmanagement. com/srm/pdf/first-live-birth-donation.pdf.
32. Woodruff TK. The Oncofertility Consortium: addressing fertility in young people with cancer. Nat Rev Clin Oncol 2010; 7:466-475.
33. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 2010; 28:4831-4841.
34. Lee S, Ozkavukcu S, Heytens E, et al. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol 2010; 28: 4683-4686.
35. American Society of Reproductive Medicine. http://www.asrm.org/uploaded Files/ASRM-Content/News-and-Publications/Practice-Guidelines/Commit tee-Opinions/Definitions-of-infertility-and-recurrent.pdf. [Accessed 12 December 2010].
36. Basco D, Campo-Engelstein L, Rodriguez S. Insuring against infertility: expanding state infertility mandates to include fertility preservation technology for cancer patients. J Law Med Ethics 2010; 38:832-839.
37. Campo-Engelstein L. Consistency in insurance coverage for iatrogenic conditions resulting from cancer treatment including fertility preservation. J Clin Oncol 2010; 28:1284-1286.
38. Peate M, Meiser B, Friedlander M, et al. Development and pilot testing of a fertility decision aid for young women diagnosed with early breast cancer. Breast J 2010.
39. Gardino SL, Jeruss JS, Woodruff TK. Using decision trees to enhance interdisciplinary team work: the case of oncofertility. J Assist Reprod Genet 2010; 27:227-231.
40. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med 2009; 360:902-911.
41. The Official Website of the Nobel Prize. http://nobelprize.org. [Accessed 5 December 2010]
42. Wennerholm UB, Soderstrom-Anttila V, Bergh C, et al. Children born after cryopreservation of embryos or oocytes: a systematic review of outcome data. Hum Reprod 2009; 24:2158-2172.
43. Patrizio P, Caplan AL. Ethical issues surrounding fertility preservation in cancer patients. Clin Obstet Gynecol 2010; 53:717-726.
44. Chian RC, Huang JY, Tan SL, et al. Obstetric and perinatal outcome in 200 infants conceived from vitrified oocytes. Reprod Biomed Online 2008; 16:608-610. (Pubitemid 351721727)
45. Cahill DJ, Wardle PG, Harlow CR, et al. Expected contribution to serum oestradiol from individual ovarian follicles in unstimulated cycles. Hum Reprod 2000; 15:1909-1912.
46. Gupta PB, Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol 2006; 102:71-78. (Pubitemid 44750648)
47. Oktay K, Buyuk E, Davis O, et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003; 18:90-95. (Pubitemid 36138857)
48. Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2007; 92:2197-2200. (Pubitemid 46997121)
49. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005; 23:3858-3859.
50. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008; 26:2630-2635.
51. Lawrenz B, Jauckus J, Kupka M, et al. Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril 2010; 94:2871-2873.
52. Madrigrano A, Westphal L, Wapnir I. Egg retrieval with cryopreservation does not delay breast cancer treatment. Am J Surg 2007; 194:477-481. (Pubitemid 47361049)
53. Baynosa J, Westphal LM, Madrigrano A, Wapnir I. Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg 2009; 209:603-607.
54. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364:1405-1410. (Pubitemid 39370715)
55. Sanchez M, Novella-Maestre E, Teruel J, et al. The Valencia programme for fertility preservation. Clin Transl Oncol 2008; 10:433-438.
56. Abir R, Feinmesser M, Yaniv I, et al. Occasional involvement of the ovary in Ewing sarcoma. Hum Reprod 2010; 25:1708-1712.
57. Woodruff TK, Shea LD. The role of the extracellular matrix in ovarian follicle development. Reprod Sci 2007; 14 (8 Suppl):6-10.
58. West ER, Xu M, Woodruff TK, Shea LD. Physical properties of alginate hydrogels and their effects on in vitro follicle development. Biomaterials 2007; 28:4439-4448. (Pubitemid 47225113)
59. Xu M, Kreeger PK, Shea LD, Woodruff TK. Tissue-engineered follicles produce live, fertile offspring. Tissue Eng 2006; 12:2739-2746. (Pubitemid 46141242)
60. Telfer EE, McLaughlin M, Ding C, Thong KJ. A two-step serum-free culture system supports development of human oocytes from primordial follicles in the presence of activin. Hum Reprod 2008; 23:1151-1158. (Pubitemid 351757334)
61. Xu M, Fazleabas AT, Shikanov A, et al. In vitro oocyte maturation and preantral follicle culture from the luteal phase baboon ovary produce mature oocytes. Biol Reprod 2010.
62. Partridge AH, Ruddy KJ. Fertility and adjuvant treatment in young women with breast cancer. Breast 2007; 16 (Suppl 2):S175-S181.
63. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005; 353:64-73. (Pubitemid 41007808)
64. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010; 122:803-811.
65. Petru E. Fertility preservation and infertility treatment in breast cancer patients. Wien Med Wochenschr 2010; 160:487-492.
66. Rosen A. Third-party reproduction and adoption in cancer patients. J Natl Cancer Inst Monogr 2005; 34:91-93.
67. Gardino SL, Russell AE, Woodruff TK. Adoption after cancer: adoption agency attitudes and perspectives on the potential to parent postcancer. Cancer Treat Res 2010; 156:153-170.